235 related articles for article (PubMed ID: 23514013)
1. Myelofibrosis: an update on current pharmacotherapy and future directions.
Cervantes F; Martinez-Trillos A
Expert Opin Pharmacother; 2013 May; 14(7):873-84. PubMed ID: 23514013
[TBL] [Abstract][Full Text] [Related]
2. How I treat myelofibrosis.
Cervantes F
Blood; 2014 Oct; 124(17):2635-42. PubMed ID: 25232060
[TBL] [Abstract][Full Text] [Related]
3. Management of myelofibrosis: JAK inhibition and beyond.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
[TBL] [Abstract][Full Text] [Related]
4. How I manage anemia related to myelofibrosis and its treatment regimens.
Verstovsek S
Ann Hematol; 2023 Apr; 102(4):689-698. PubMed ID: 36786879
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for myelofibrosis.
Atallah E; Verstovsek S
Expert Opin Emerg Drugs; 2012 Dec; 17(4):555-70. PubMed ID: 23186315
[TBL] [Abstract][Full Text] [Related]
6. New drugs for the treatment of myelofibrosis.
Mesa RA
Curr Hematol Malig Rep; 2010 Jan; 5(1):15-21. PubMed ID: 20425392
[TBL] [Abstract][Full Text] [Related]
7. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM
Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
9. Clarifying the use of ruxolitinib in patients with myelofibrosis.
Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Vaddi K; Sarlis NJ; Gupta V
Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
[TBL] [Abstract][Full Text] [Related]
11. State-of-the-Art Review on Myelofibrosis Therapies.
Wang F; Qiu T; Wang H; Yang Q
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic management of myelofibrosis.
Leung M; Highsmith K; Rexwinkle A
J Oncol Pharm Pract; 2017 Dec; 23(8):591-601. PubMed ID: 27672139
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ruxolitinib for myelofibrosis.
Santos FP; Verstovsek S
Expert Opin Pharmacother; 2014 Jul; 15(10):1465-73. PubMed ID: 24856675
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
Saleh K; Ribrag V
Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
[TBL] [Abstract][Full Text] [Related]
17. Myelofibrosis: diagnosis and treatment.
Barranco-Lampón G; Martínez-Castro R; Arana-Luna L; Álvarez-Vera JL; Rojas-Castillejos F; Peñaloza-Ramírez R; Carballo-Zarate AA; Olarte-Carrillo I; Minamy JI; López-Salazar J; Navarrete JJ; Espinosa-Partida A; Ventura-Enríquez Y; Ruiz-Contreras JI; Aguirre-Reyes OG; Anaya-Cuéllar I; Aguilar-Luévano J; Díaz-Ramírez HF; Herrera-Olivares W; Aguilar-Hidalgo JA; Alcívar-Cedeño LM; Hernández-Caballero Á; Galaz-Cordero LE; Peña-Celaya JA; Báez-Islas PE; Bates-Martín RA; Cano-León AML; Espitia-Ríos ME; Barbosa D; Morales-Adrián J; Pacheco MJ; Delgado-López N; Neme-Yunes Y; Moralws-Hernández AE; Mújica-Martínez A; Pérez-Lizardi AB; Pérez-Gómez KD; Barragán-Ibáñez G; Martínez A; Flores-Ordúñez K; Ramírez-Hoyos P; Rosales-López MLÁ; Acosta-Maldonado BL; Jiménez-Ochoa MA; Garzón-Velásquez KB; Hernández-Ruiz E; McNally-Guillén BM; Saucedo-Montes EE; Aguilar-Andrade C; Vivas-Arteaga CL; Guerra-Alarcón LV; Milán-Salvatierra AI; Campa-Monroy DI; Cota-Rangel X; Estrada-Domínguez P; García-Camacho AS; García-Castillo C; Banda-García LI; Rodríguez-Sánchez V; Meillón-García LA; Urbina-Escalante E; Martínez-Ramírez MA; Loera-Fragoso SJ; Martínez-Coronel J; Zapata-Canto N; Gómez-Cortés SC; Medina-Coral JE; Mójica-Balderas L; Pérez-Zúñiga JM; Pérez FJ; López-Arroyo JL; Zazueta-Pozos JF; Romero-Martínez E; Romero-Rodelo H; Tapia-Enríquez AL; Soriano-Mercedes EJ; Salazar-Ramírez Ó; Vilchis-González SP; Tepepa-Flores F; Alvarado-Ibarra M
Gac Med Mex; 2022; 158(Supl 1):26-37. PubMed ID: 37734057
[TBL] [Abstract][Full Text] [Related]
18. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
Lancman G; Mascarenhas J
Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
[TBL] [Abstract][Full Text] [Related]
19. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.
Morsia E; Gangat N
Expert Opin Ther Targets; 2021 Mar; 25(3):211-222. PubMed ID: 33844952
[No Abstract] [Full Text] [Related]
20. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
